Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of nimotuzumab with neoadjuvant and concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma
ChiCTR2500104179Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in Cervical Cancer (CC), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: 3-year progression-free survival rate and Safety. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500104179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104179.